Perrigo ROA 2010-2024 | PRGO
Current and historical return on assets (ROA) values for Perrigo (PRGO) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Perrigo ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2024-09-30 | $-0.16B | $11.20B | -1.48% |
| 2024-06-30 | $-0.12B | $10.40B | -1.16% |
| 2024-03-31 | $-0.01B | $10.64B | -0.07% |
| 2023-12-31 | $-0.01B | $10.81B | -0.12% |
| 2023-09-30 | $-0.01B | $10.76B | -0.05% |
| 2023-06-30 | $-0.07B | $10.97B | -0.62% |
| 2023-03-31 | $-0.14B | $10.96B | -1.29% |
| 2022-12-31 | $-0.14B | $11.02B | -1.30% |
| 2022-09-30 | $-0.11B | $10.68B | -1.00% |
| 2022-06-30 | $-0.12B | $10.92B | -1.09% |
| 2022-03-31 | $-0.11B | $10.39B | -1.01% |
| 2021-12-31 | $-0.07B | $10.43B | -0.63% |
| 2021-09-30 | $-0.25B | $10.92B | -2.26% |
| 2021-06-30 | $-0.35B | $11.23B | -3.07% |
| 2021-03-31 | $-0.23B | $11.33B | -1.99% |
| 2020-12-31 | $-0.16B | $11.49B | -1.40% |
| 2020-09-30 | $-0.01B | $11.58B | -0.06% |
| 2020-06-30 | $0.24B | $12.13B | 2.08% |
| 2020-03-31 | $0.19B | $11.40B | 1.65% |
| 2019-12-31 | $0.15B | $11.30B | 1.29% |
| 2019-09-30 | $0.25B | $11.31B | 2.20% |
| 2019-06-30 | $0.09B | $11.43B | 0.78% |
| 2019-03-31 | $0.11B | $11.12B | 1.03% |
| 2018-12-31 | $0.13B | $10.98B | 1.17% |
| 2018-09-30 | $0.12B | $10.94B | 1.07% |
| 2018-06-30 | $0.24B | $11.23B | 2.03% |
| 2018-03-31 | $0.13B | $11.64B | 1.10% |
| 2017-12-31 | $0.12B | $11.63B | 0.97% |
| 2017-09-30 | $-1.31B | $11.84B | -10.19% |
| 2017-06-30 | $-2.95B | $11.79B | -21.23% |
| 2017-03-31 | $-3.41B | $13.98B | -22.00% |
| 2016-12-31 | $-4.01B | $13.87B | -23.76% |
| 2016-09-30 | $-2.83B | $15.89B | -15.48% |
| 2016-06-30 | $-0.98B | $18.29B | -5.08% |
| 2016-03-31 | $-0.46B | $19.50B | -2.37% |
| 2015-12-31 | $0.04B | $19.35B | 0.23% |
| 2015-09-30 | $0.29B | $19.70B | 1.59% |
| 2015-06-30 | $0.12B | $19.72B | 0.74% |
| 2014-12-31 | $0.21B | $16.46B | 1.48% |
| 2014-09-30 | $0.06B | $13.78B | 0.42% |
| 2013-12-31 | $0.14B | $13.71B | 1.89% |
| 2013-09-30 | $0.33B | $5.51B | 6.70% |
| 2012-12-31 | $0.33B | $4.29B | 7.96% |
| 2012-09-30 | $0.32B | $4.12B | 7.99% |
| 2011-12-31 | $0.26B | $3.94B | 7.57% |
| 2011-09-30 | $0.25B | $3.51B | 7.86% |
| 2010-12-31 | $0.23B | $2.94B | 8.00% |
| 2010-09-30 | $0.20B | $2.77B | 7.28% |
| 2009-12-31 | $0.16B | $2.46B | 6.51% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.510B | $4.656B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $194.987B | 24.87 |
| Stryker (SYK) | United States | $136.147B | 30.68 |
| Boston Scientific (BSX) | United States | $130.670B | 37.57 |
| EssilorLuxottica (ESLOY) | France | $110.026B | 0.00 |
| Medtronic (MDT) | Ireland | $102.570B | 15.24 |
| Haleon (HLN) | United Kingdom | $43.909B | 28.53 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.293B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $35.376B | 18.35 |
| ResMed (RMD) | United States | $33.995B | 27.93 |
| Terumo (TRUMY) | Japan | $28.800B | 40.67 |
| Koninklijke Philips (PHG) | Netherlands | $23.527B | 18.01 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.064B | 13.41 |
| Insulet (PODD) | United States | $17.996B | 71.67 |
| Baxter (BAX) | United States | $14.756B | 9.60 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.838B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.021B | 40.32 |
| Bio-Rad Laboratories (BIO) | United States | $9.125B | 31.01 |
| Demant (WILYY) | Denmark | $7.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.392B | 14.85 |
| Prestige Consumer Healthcare (PBH) | United States | $3.886B | 19.33 |
| Haemonetics (HAE) | United States | $3.862B | 18.85 |
| ICU Medical (ICUI) | United States | $3.751B | 35.71 |
| Envista Holdings (NVST) | United States | $3.103B | 23.11 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.894B | 18.63 |
| GN Store Nord (GNNDY) | Denmark | $2.864B | 18.36 |
| Neogen (NEOG) | United States | $2.605B | 30.05 |
| LeMaitre Vascular (LMAT) | United States | $2.074B | 50.41 |
| Green Thumb Industries (GTBIF) | United States | $1.630B | 28.52 |
| AtriCure (ATRC) | United States | $1.465B | 0.00 |
| InMode (INMD) | Israel | $1.444B | 8.68 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.371B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.304B | 9.32 |
| BioLife Solutions (BLFS) | United States | $1.211B | 0.00 |
| Owens & Minor (OMI) | United States | $0.973B | 7.60 |
| CeriBell (CBLL) | United States | $0.958B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.955B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.883B | 15.58 |
| Evolus (EOLS) | United States | $0.688B | 0.00 |
| Omeros (OMER) | United States | $0.593B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.593B | 26.15 |
| Capricor Therapeutics (CAPR) | United States | $0.587B | 0.00 |
| Surmodics (SRDX) | United States | $0.572B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.445B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.429B | 0.00 |
| Quanterix (QTRX) | United States | $0.383B | 0.00 |
| ZimVie (ZIMV) | United States | $0.373B | 31.44 |
| Valneva SE (VALN) | France | $0.353B | 0.00 |
| Biote (BTMD) | United States | $0.313B | 6.86 |
| Viemed Healthcare (VMD) | United States | $0.312B | 29.70 |
| Canopy Growth (CGC) | Canada | $0.295B | 0.00 |
| Cerus (CERS) | United States | $0.293B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.283B | 18.95 |
| Sanara MedTech (SMTI) | United States | $0.276B | 0.00 |
| Zynex (ZYXI) | United States | $0.268B | 56.00 |
| High Tide (HITI) | Canada | $0.237B | 98.00 |
| Aurora Cannabis (ACB) | Canada | $0.225B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.211B | 14.54 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Organigram Holdings (OGI) | Canada | $0.184B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.181B | 0.00 |
| Brainsway (BWAY) | Israel | $0.169B | 89.60 |
| FitLife Brands (FTLF) | United States | $0.151B | 19.04 |
| Jin Medical (ZJYL) | China | $0.132B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.110B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.104B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.79 |
| Veru (VERU) | United States | $0.092B | 0.00 |
| Exagen (XGN) | United States | $0.083B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.066B | 34.17 |
| InterCure (INCR) | Israel | $0.061B | 0.00 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.054B | 0.00 |
| Modular Medical (MODD) | United States | $0.050B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.048B | 0.00 |
| Safety Shot (SHOT) | United States | $0.042B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.82 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |